Brief: Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
05/02/2025 14:07
Feb 5 (Reuters) - Shanghai Henlius Biotech Inc
2696.HK :
* SERPLULIMAB APPROVED IN THE EU FOR FIRST-LINE TREATMENT OF
EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Source text: ID:nPn1dClhYa
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln